Report Highlights
-
There are at least 39 terrorist groups with about 250,000 members worldwide.
-
Prior to attack, a vaccine would cost $2.80 per person.
-
After an attack, antibiotic and antiviral treatment could cost $21,386 per person.
-
Mass small pox casualties in the metropolitan New York City region could cost $151 billion in 2007.
INTRODUCTION
Large scale terrorist attacks in the U.S. became a reality in September 2001, bringing with them fear, uncertainty and heightened awareness. Terrorists have used a variety of weapons to inflict harm upon others. Today, however, there is growing concern over the possibility of bioterrorist attacks. Such weapons of mass destruction include biological, chemical and nuclear agents, the impact of which could be staggering. This significantly has altered strategies for treatment that both companies and the government are using to address this issue. BCC's study covers the consequences of a future event, identifying the impact on major metropolitan areas and the costs involved. It demonstrates how the government, academia, pharmaceutical industry participants and the general public are working together in this very important area. It also identifies pharmaceutical products currently available and products in development to counter bioterrorism.
BCC presents a comprehensive look at the markets and strategies for U.S. bioterrorism treatments. These markets are divided into the various types of bioterrorism agents that present a threat to the U.S. and other nations. Deviating from the normal market reports presented by BCC, this report is based largely on what might happen in the event of a widespread bioterrorism attack on the United States in major metropolitan areas. It identifies the areas of bioterrorism treatment that have substantial competitors and products available, and also targets segments of bioterrorism where there are emergent needs. It estimates the potential revenues that could be generated should a bioterrorism attack occur. Each segment is broken down into the cost per treatment and multiplied by the estimated number of victims and the number that would have to be treated in a given geographical area. This formula could be applied to any known population to extrapolate potential revenues in the event of an outbreak.
The report presents insights into areas for current and future development, and is directed to decision-makers, developers and strategists, as well as directors of research in the various biological, chemical and nuclear segments. The report will be especially useful to developing biotech firms that want to enter the area of bioterrorism treatments.
SCOPE OF STUDY
This report provides coverage of:
- The different areas of bioterrorism and an explanation of each
- Risk factors and the incidence and mortality
- R&D in potential treatments in response to biological, chemical and nuclear weapons
- Current and potential market size and market strategies in the U.S.
- Forecasts for 2001, 2005 and 2015
- The industry, its relationship to the healthcare industry, its participants and its future trends.
METHODOLOGY AND INFORMATION SOURCES
The information and analysis presented in this BCC report are based on extensive first-hand interviews with primary executives, product managers, government experts and participating organization executives. Background information was obtained from various government, , medical journal and trade magazines and interviews with disaster personnel. Key information from published literature was used to conduct interviews with over 50 industry participants to validate and obtain expert opinions on current and future trends. All information gathered was used to extrapolate figures for the 2005 and 2015 markets in the event of a bioterrorism attack on major metropolitan areas. The figures are by no means exact but are derived from analyst calculations based on all information gathered.
All market data pertain to the U.S. market at the manufacturers' level. Data are expressed in current U.S. dollars. The base year was 2001; there was no historical data because prior to 2001, there had been no bioterrorist attack of this magnitude. Forecast data are provided for 2005 and 2015 based on the products in development and the populations affected.
ANALYST CREDENTIALS
Mary Anne Crandall is a Medical Analyst specializing in the pharmaceutical industry for the last 10 years. She has completed several in-depth studies on various medical topics requiring both great medical expertise and excellent knowledge of the industry. Mary Anne Crandall is a Registered Nurse and is currently teaching at a prestigious university.
Related Reports
Recent Reports
Forensic Technologies: New and Growing Markets
The global market for forensics technology is estimated to increase from $20.9 billion in 2022 to reach $42.1 billion by 2027, at a compound annual growth rate (CAGR) of 15.0% from 2022 through 2027.
Surveillance and Monitoring of Chemical, Biological, Radiological, Nuclear, and Explosive (CBRNE) Hazards
The global chemical, biological, radiological, nuclear and explosive (CBRNE) equipment market should reach $25.4 billion by 2027 from $19.0 billion in 2022 at a compound annual growth rate (CAGR) of 5.9% for the forecast period of 2022 to 2027.
Identity Verification: Global Markets
The global identity verification market should reach $17.7 billion by 2026 from $8.0 billion in 2021 at a compound annual growth rate (CAGR) of 17.1% for the forecast period of 2021 to 2026.
Global Video Surveillance and VSaaS Market
The global market for video surveillance systems and VSaaS should grow from $40.0 billion in 2020 to $76.1 billion by 2025, at compound annual growth rate (CAGR) of 13.8% for the period of 2020-2025.
Anti-counterfeiting, Authentication and Verification Technologies
The global anti-counterfeiting, authentication and verification technologies market should grow from $105.9 billion in 2018 to $184.6 billion by 2023 at a compound annual growth rate (CAGR) of 11.8% for the period of 2018-2023.
Top Trending Reports
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for cell and gene therapy tools and reagents is estimated to grow from $8.3 billion in 2022 to $13.7 billion in 2027, with a compound annual growth rate (CAGR) of 10.6% for the period of 2022-2027.
ESG Trends in Chemical Industry
This report focuses on the ESG trends in the chemical industry and evaluates the ESG implementation including current and future potential. The report utilizes various databases, including sustainability reports, annual reports, and other indicators used to develop the current market. The study provides detailed information on the main factors influencing ESG growth in the chemical industry. It enables the reader to understand the industry in general while also providing insight into the inter-relationship between ESG and the sustainable chemical industry. The report describes market growth, developing trends, industry leaders, and applications of ESG implementation in the chemical industry.
Digital Pathology: Technologies and Global Markets
The global digital pathology market is estimated to increase from $5.9 billion in 2022 to reach $10.7 billion by 2027, at a compound annual growth rate (CAGR) of 12.5% from 2022 through 2027.
Smartphone-Based Patient Monitoring: Global Market
The global smartphone-based patient monitoring market should reach $21.5 billion by 2027 from $6.8 billion in 2022 at a compound annual growth rate (CAGR) of 25.9% for the forecast period of 2022 to 2027.
Non-Fungible Tokens (NFT): Global Market
The global NFTs market should reach $37.6 billion by 2022 and $125.6 billion by 2027, with a compound annual growth rate (CAGR) of 27.3% during the forecast period of 2022-2027.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More